(Reuters) – Pfizer Inc said on Wednesday it was pausing patient recruitment in new and ongoing global studies for three weeks due to the coronavirus outbreak.
The decision would exclude select studies that are recruiting patients with life-threatening conditions who have few or no other therapeutic options, the U.S. drugmaker said in an emailed statement.
(Reporting by Manas Mishra in Bengaluru and Michael Erman in Maplewood, New Jersey; Editing by Vinay Dwivedi)
